NEW YORK (TheStreet) -- Ebola is here, so for daytraders of biotech and drug stocks, Wednesday is going to be their Best. Day. Ever.

A guy traveling from Liberia to Dallas was diagnosed with the Ebola virus, we learned last night. Fortunately, the U.S. health care system is better equipped than West Africa to deal with contagious viruses, so virologists aren't overly concerned about the appearance of Ebola on our shores. But hey, there's money to be made trading stocks based on fear and headlines, so expect some crazy volatility today.

I've written already about Tekmira Pharmaceuticals (TKMR) and its work on a legit, experimental Ebola therapy. Tekmira would prefer not to be pegged as an Ebola company, good luck with that request Wednesday. Tekmira shares are up 20% to $25.43. Sarepta Therapeutics (SRPT) - Get Report is also working on an experimental Ebola therapy. Shares opened up 2% to $21.52.

At this point, any drug stock even tangentially connected to Ebola is getting a lift. Let's run down the list: BioCryst Pharmaceuticals (BCRX) - Get Report +3%, NewLink Genetics (NLNK) - Get Report +9%, Hemispherx Biopharma (HEB) +14%, Inovio Pharmaceuticals (INO) - Get Report +2.5%, NanoViricides (NNVC) - Get Report +9% and hazmat suit maker Lakeland Industries (LAKE) - Get Report +11%.

Odds are better that I have a cure for Ebola in the back of my fridge than most of these do-nothing companies have for contributing something real to the fight against the virus; but traders need to eat, too.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.